国家医保目录新增114种药品：5款百万元CAR-T疗法纳入商保，企业代表直呼这是“重要里程碑”

Core Insights - The 2025 National Medical Insurance Directory has added 114 new drugs, including 50 innovative drugs, which will significantly enhance patient access to essential medications [1][3][6] - The introduction of the Commercial Health Insurance Innovative Drug Directory marks a pivotal moment for the pharmaceutical industry, allowing for new payment channels beyond traditional insurance [11][12] Summary by Sections National Medical Insurance Directory - The 2025 National Medical Insurance Directory includes 114 new drugs, with 50 classified as innovative drugs, such as Tislelizumab and domestic ADCs [1][3] - The total number of drugs in the National Medical Insurance Directory has increased to 3,253, with significant improvements in coverage for critical areas like oncology and rare diseases [6] Commercial Health Insurance Innovative Drug Directory - The Commercial Health Insurance Innovative Drug Directory features five CAR-T cell therapies and two imported Alzheimer's drugs, addressing previously limited access due to high costs [1][7] - The directory aims to enhance the accessibility of high-value innovative drugs, with a focus on improving patient affordability [9][10] Industry Impact - The inclusion of innovative drugs in the National Medical Insurance Directory is expected to accelerate the transition from laboratory to patient access, providing crucial support for sustainable investment in pharmaceutical R&D [2][4] - The launch of the Commercial Health Insurance Innovative Drug Directory allows pharmaceutical companies to explore new payment avenues, fostering a dual-track pricing system that recognizes the value of innovative therapies [12] Company Responses - Companies like WuXi AppTec and CanSino Biologics have expressed optimism about the new directories, highlighting the government's support for domestic innovation and the potential for improved patient outcomes [4][5][11] - The introduction of the directories has prompted companies to collaborate closely with insurance providers to ensure effective implementation and patient access [12]